Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
167 Leser
Artikel bewerten:
(0)

Unchained Labs lands another win in the biologics stability market! Acquires AVIA Biosystems

PLEASANTON, California, June 4, 2015 /PRNewswire/ -- Unchained Labs upped its game in the biologics stability market today, announcing the acquisition of AVIA Biosystems, the developer of the Isothermal Chemical Denaturation (ICD) system for measuring biologic stability. This is the second acquisition for Unchained Labs this year.

The ICD system makes something that wasn't possible before - the routine measurement of protein stability under denaturing conditions - totally doable. It completely automates the complex sample prep and data analysis needed to make these measurements, giving formulation scientists a true walk-away solution. The ICD system is also a perfect complement for Unchained Labs' first product, the UNit, which simultaneously measures the top two biologic stability indicators, protein unfolding and aggregation temperatures.

"We are totally committed to improving biologics characterization tools and the ICD is a great new tool that can actually help predict future drug stability," said Tim Harkness, Founder and CEO of Unchained Labs. "The ICD and the UNit are a perfect pairing and really help establish us as the experts in protein stability. We have done a lot and done it quickly at Unchained Labs, but we are unwavering in our pledge to acquire any product or business that can make a real difference for biologics researchers."

"I'm really looking forward to joining forces with the Unchained Labs team," said Dr. Rick Brown, Co-founder and President of AVIA Biosystems. "Together, our products will give drug discovery researchers the power to characterize and understand their biologics better than they ever could before."

Unchained also announced the addition of $6 million to its Series A Financing, bringing the total Series A round to $31M. The original syndicate partners, Novo Ventures, Canaan Partners and TPG Biotech all participated in the financing.

About Unchained Labs
Unchained Labs is committed to building the first cool biologics tools company. One that matters. One without old school rules. One with products that'll make a real difference in the research scientists do every day. We plan to buy businesses and product lines and then add our magic touch for developing breakthrough products and selling them like crazy. We are located in Pleasanton, CA and can be found online at www.unchainedlabs.com.

Contact:
Taegen Clary
Sr. Director of Marketing, Unchained Labs
taegen.clary@unchainedlabs.com
+1.925.587.9806

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2015 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.